Genprex Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Genprex stock.
View analyst ratings for Genprex or view top-rated stocks.

Wall Street analysts have given Genprex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Genprex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Genprex saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 3,270,000 shares, a decrease of 22.0% from the January 28th total of 4,190,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is presently 1.9 days.
View Genprex's Short Interest.

Genprex is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Genprex.

Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Monday, April, 1st. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.10.
View Genprex's earnings history.

Genprex's stock was trading at $2.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNPX stock has increased by 111.2% and is now trading at $5.11.
View which stocks have been most impacted by COVID-19.

3 analysts have issued 1 year price objectives for Genprex's shares. Their forecasts range from $5.00 to $7.00. On average, they expect Genprex's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for Genprex or view top-rated stocks among Wall Street analysts.

Some companies that are related to Genprex include Prothena (PRTA), ESSA Pharma (EPIX), Lexicon Pharmaceuticals (LXRX), Humanigen (HGEN), Amphastar Pharmaceuticals (AMPH), ADVANZ PHARMA (CXRXF), Five Prime Therapeutics (FPRX), Kadmon (KDMN), AnaptysBio (ANAB), Esperion Therapeutics (ESPR), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), VBI Vaccines (VBIV), Provention Bio (PRVB) and Gossamer Bio (GOSS).
View all of GNPX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Genprex's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.92%), Northern Trust Corp (0.86%), Wells Fargo & Company MN (0.29%), Nuveen Asset Management LLC (0.23%), Bank of New York Mellon Corp (0.23%) and First Trust Advisors LP (0.22%).
View institutional ownership trends for Genprex.

GNPX stock was sold by a variety of institutional investors in the last quarter, including IHT Wealth Management LLC, Price T Rowe Associates Inc. MD, Barclays PLC, and First Trust Advisors LP.
View insider buying and selling activity for Genprex or view top insider-selling stocks.

GNPX stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., JPMorgan Chase & Co., QS Investors LLC, Bank of New York Mellon Corp, Virtu Financial LLC, Resources Investment Advisors LLC., and Northern Trust Corp.
View insider buying and selling activity for Genprex or or view top insider-buying stocks.

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GNPX stock can currently be purchased for approximately $5.11.

Genprex has a market capitalization of $221.15 million. The company earns $-10,650,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

Genprex employs 8 workers across the globe.

The official website for Genprex is www.genprex.com.

Genprex is headquartered at 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712.

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-537-7997 or via email at [email protected]